33 Investor presentation First three months of 2025 Pipeline supports significant grow strategic focus areas PHASE 1 NN1644 – GSI NN1471 – Pumpsulin NN9041 – DNA Immunotherapy NN9490 – Sc. Amycretin NN9487 – Oral Amycretin NN9441 – INV-347 NN9638 – Amylin 355 NN9839 – Amylin 1213 NN9662 – Triple NN9559 – UBT251 (GGG tri-agonist) 11 NN6582 – LXR(a) in MASH NN6581 – MARC1 in MASH NN9003 – Stem Cells in HF NN9001 – Stem Cells in PD NN6491 – Anti ANGPTL3 in CVD NN6022 – Ventus NLRP3i in CVD NN6537 – CNP in HF NN7442 – Inno8 NN7614 – TMPRSS6 RNAi PHASE 2 NN9541 – OW GIP/GLP-1 co-agonist NN9506 – FUSE 10 NN9440 – Monlunabant NN9490 – Sc. Amycretin NN9487 – Oral Amycretin NN9542 – OW GIP/GLP-1 co-agonist NN9440 – Monlunabant NN9505 – FUSE 10 NN6706 – CDR132L NN9500 – Zalfermin NN6019 – ATTR Cardiomyopathy NN7533 – NDec in SCD NN7536 – Etavopivat in Thalassemia PHASE 3 NN9388 – CagriS NN9924 – Oral S NN9536 – Sema NN9838 – CagriS NN9932 – Oral S NN6535 – Oral S NN6018 – Ziltive NN6018 – Ziltive NN6018 – Ziltive NN7769 – Mim8 NN7535 – Etavo Other PHASE FOCUS – Semag Diabetes care Obesity care Rare blood disorders Rar 1 Submitted to EMA 2 CRL received in the US 3 Submitted to EU and US for HA/HB 4 Approved for PH1 by FDA 5 Approved in the EU, Chi January 2025. STEP HFpEF label update reflected in EU label based on positive CHMP opinion received in Q3 2024 8 Submitted in US AATLD: Alpha-1 Antitrypsin Deficiency-associated Liver Disease; AD: Alzheimer’s Disease; ANGPTL3: Angiopoietin -like protein 3; AMI kidney disease; CVOT: Cardiovascular outcome trial; FGF-21: Fibroblast growth factor 21; GHD: Growth hormone disorder; GSI: Gluc Haemophilia with inhibitors; LXR(a): Liver X receptor alpha; MARC1: Mitochondrial amidoxime reducing component 1; MASH: Metab Peripheral arterial disease; PD: Parkinson’s Disease; PH: Primary hyperoxaluria; SC: Subcutaneous; SCD: Sickle cell disease; Sema: Se
Download PDF file